Visão geral da empresa
Rapid Micro Biosystems, Inc. operates as a life sciences technology company focused on providing specialized products for the detection of microbial contamination within the manufacturing processes of pharmaceuticals, biologics, medical devices, and personal care products. The company serves a global client base with operations and product distribution spanning the United States, Switzerland, Germany, Japan, and various international markets. Its business is categorized within the Healthcare sector, specifically under the Medical Devices industry, which implies a reliance on rigorous regulatory compliance and high technical standards in production. The firm maintains a market capitalization of $103.20M and generates annual revenue of $33.59M while employing a workforce of 171 individuals. These valuation and revenue figures position the company as a mid-sized entity within its niche, indicating a relatively small scale compared to large-cap healthcare conglomerates but suggesting a specialized market presence that allows for significant year-over-year expansion potential.
Saúde financeira
The company reported a revenue of $33.59M for the trailing twelve months, yet this top-line figure is contrasted sharply by a net income of $-47,123,000 and an EBITDA of $-44,640,000, revealing a substantial gap between gross sales and bottom-line profitability driven by high operating expenses. The free cash flow stands at $-15,771,250, which indicates that the company is currently burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility and reliance on external capital sources or existing cash reserves. Profitability metrics reflect this challenge with a gross margin of 3.1%, an operating margin of -108.2%, and a profit margin of -140.3%; the negative operating and profit margins suggest that operating costs are significantly exceeding gross profits, a structure often seen in early-stage growth companies or those undergoing aggressive market expansion. Regarding the balance sheet, the company holds $38.73M in cash against $23.87M in debt, resulting in a debt-to-equity ratio of 71.90, which suggests a leveraged position where equity is lower than the total debt burden, though the cash reserve provides a buffer against short-term obligations. The current ratio is reported at 3.31, indicating that the company possesses more than three times the current assets necessary to cover its current liabilities, which points to robust short-term liquidity despite the negative earnings. Furthermore, the return on equity is -86.8% and the return on assets is -34.2%, metrics that reveal that management is currently generating negative returns on the capital invested in the business, reflecting the operational losses inherent in the current financial period.
Avaliação de valorização
The valuation metrics for Rapid Micro Biosystems, Inc. present a complex picture given the negative earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -2.87, implying that the market is pricing the stock based on future expectations of earnings recovery rather than historical profitability. The price-to-book ratio is 3.04, which indicates that the stock is trading at a significant premium over its book value, suggesting that investors are valuing the company's intangible assets, such as its proprietary technology and patent portfolio, at a rate higher than the tangible assets on its balance sheet. Alternative valuation measures include a price-to-sales ratio of 3.07 and an EV/EBITDA of -1.98; these metrics suggest that the market is willing to pay a multiple of over three times its revenue despite the lack of current earnings, a valuation approach common for companies in high-growth phases where revenue expansion is prioritized over immediate profitability. In terms of price movement, the stock has a 52-week high of $4.94 and a 52-week low of $1.86, meaning the current price sits between these extremes, reflecting the volatility typical of small-cap healthcare stocks. The beta value is 1.60, which indicates that the stock's price volatility is substantially higher than that of the broader market, moving 60% more than the market index on average during periods of fluctuation.
Growth & Income
The company demonstrated robust revenue growth with a year-over-year increase of 37.3%, while earnings growth is N/A due to the negative net income reported in the trailing twelve months. The absence of earnings growth data in conjunction with strong revenue expansion implies that the company is in a phase where top-line scaling is occurring faster than cost efficiencies are realized, a pattern typical of businesses investing heavily in R&D and market penetration. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute profits to shareholders but instead retains all earnings to fund operations and strategic initiatives. This reinvestment strategy aligns with the company's financial profile where cash is being utilized to sustain operations rather than being returned via dividends. Overall, the growth and income profile of Rapid Micro Biosystems, Inc. is characterized by significant revenue acceleration and a complete absence of dividend income, relying on potential future profitability improvements to support shareholder value.